Sofwave Medical Ltd, a leader in energy-based non-invasive, aesthetic medical devices, has received approval from Japan’s PMDA to market its SUPERB™ Technology in Japan, expanding their reach in the APAC region. This approval opens up significant growth opportunities for the company in one of the world’s largest medical technology markets. With a strong go-to-market strategy and growing distribution network, Sofwave is poised to expand its commercial footprint in the region.
According to the ISAPS global surveys, Japan is the third largest market for non-surgical medical aesthetic procedures and has a high number of plastic surgeons, making it a key market for Sofwave’s innovative technologies. The company’s SUPERB™ Technology, using Synchronous Ultrasound Parallel Beam technology, is FDA-cleared for improving facial lines and wrinkles, lifting eyebrows and lax submental tissue, and improving the appearance of cellulite and acne scars. Sofwave’s products provide physicians with safe and effective aesthetic solutions for their patients.
Sofwave’s CEO, Louis Scafuri, expressed excitement about entering the Japanese market and expanding the company’s presence in the APAC region. With the increasing demand for minimally invasive aesthetic procedures and the adoption of new weight loss medications, Sofwave is well-positioned to capitalize on the growing market opportunities. Investors and stakeholders can contact the company for more information on their products and growth strategies.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
